Despite challenges from the Trump administration's policies, tariffs and research funding cuts, the biotech market shows resilience with potential growth drivers. Investors remain focused on later-stage, derisked assets while showing particular interest in obesity treatments and cancer therapies.
|
|
|
-
Lilly’s former small molecule head makes the leap to a rising biotech in obesity
-
Biotechs emerging from stealth take aim at pharma’s prime targets
-
After an up and down year, pharma’s R&D landscape is shifting again
|
|
This Trendline is independently produced by our journalists. The support of our sponsors makes this journalism possible. Want to learn about sponsorship opportunities? Contact us directly at advertising@industrydive.com.
|
|
|
|
